To determine whether ARP2/3 mediates Ang1-driven cancer motility, we knocked down ARPC3, a subunit of ARP2/3, using ARPC3-specific shRNA in SW620 and COLO320DM cancer cells (Figure 3a,b), followed by scratch assay [17,24,25,26] (Figure 3c,d). This evidence concerns the gene ACTR2 and cancer.